EARLY T-CELL PRECURSOR LEUKEMIA: A SUBTYPE OF VERY HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIED IN TWO INDEPENDENT COHORTS
暂无分享,去创建一个
Cheng | J. Downing | F. Behm | S. Raimondi | D. Campana | Xiaoping Su | C. Mullighan | G. Basso | E. Coustan-Smith | D. Pei | J. Rubnitz | M. Onciu | A. Biondi
[1] T. Ikawa,et al. Adult T-cell progenitors retain myeloid potential , 2008, Nature.
[2] A. Bhandoola,et al. The earliest thymic progenitors for T cells possess myeloid lineage potential , 2008, Nature.
[3] Elizabeth-sharon Fung. Molecular dissection of prethymic progenitor entry into the T lymphocyte developmental pathway , 2008 .
[4] Ellen V. Rothenberg,et al. Launching the T-cell-lineage developmental programme , 2008, Nature Reviews Immunology.
[5] L. Chin,et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers , 2007, Nature.
[6] Christopher B. Miller,et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.
[7] M. Schrappe,et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Bloomfield,et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Muckenthaler,et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. , 2006, Blood.
[10] J. V. van Dongen,et al. Human thymus contains multipotent progenitors with T/B lymphoid, myeloid, and erythroid lineage potential. , 2006, Blood.
[11] J. Downing,et al. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Rolink,et al. The earliest subpopulation of mouse thymocytes contains potent T, significant macrophage, and natural killer cell but no B-lymphocyte potential. , 2005, Blood.
[14] Gordon K. Smyth,et al. limma: Linear Models for Microarray Data , 2005 .
[15] Cheng Cheng,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.
[16] A. Ferrando,et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. , 2004, Blood.
[17] Freddy Radtke,et al. Notch regulation of lymphocyte development and function , 2004, Nature Immunology.
[18] M. Caligiuri,et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia , 2004, The Lancet.
[19] F. Speleman,et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. , 2004, Blood.
[20] R. Gelber,et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[22] E. Lander,et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.
[23] F. Behm,et al. Immunophenotyping of leukemia. , 2000, Journal of immunological methods.
[24] F. Behm,et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. , 2000, Blood.
[25] A. Look,et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study , 1999, Leukemia.
[26] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[27] W. Hop,et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.
[28] A. Órfão,et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). , 1998, Blood.
[29] Elaine Coustan-Smith,et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.
[30] H. Sather,et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] F. Mandelli,et al. Good steroid response in vivo predicts a favorable outcome in children with T‐cell acute lymphoblastic leukemia , 1995 .
[32] F. Behm,et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. , 1993, Blood.
[33] C. Pui,et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. , 1993, Leukemia.
[34] J. Shuster,et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1990, Blood.
[35] E. Thiel,et al. Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. , 1989, Blood.
[36] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .
[37] J. Burchenal,et al. Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.